Julaay 2022: Dabrafenib (Tafinlar, Novartis) iyo trametinib (Mekinist, Novartis) waxay ogolaansho degdeg ah ka heleen Maamulka Cuntada iyo Dawooyinka ee daawaynta bukaanada qaangaarka ah iyo carruurta ee ka weyn 6 sano ee qaba xanuun la'aan.
Juun 2022: Laba ama in ka badan oo daawaynta habaysan ka dib, FDA waxay siisay tisagenlecleucel (Kymriah, Novartis Pharmaceuticals Corporation) oo dadajisay oggolaanshaha bukaanada qaangaarka ah ee dib u soo noqday ama dib u soo noqday follicular lymphoma (FL).T.
Abriil 2022: Maamulka Cuntada iyo Dawooyinka ayaa ansixiyay Pluvicto (lutetium Lu 177 vipivotide tetraxetan, Advanced Accelerator Applications USA, Inc., shirkad Novartis) ee daaweynta bukaanada qaangaarka ah ee leh mem prostate-gaar ah.
Maarso 2022: Habka kacaanka ee daawaynta unug ee CAR-T waxay awood u leedahay inay rogaan waxa noqday axiom caafimaad: in daawaynta saamaynta cajiibka leh ee burooyinka ay ku timaaddo kharashyada khataraha la taaban karo ee bukaan socodka.
Immunotherapy ee daawaynta kansarka Kansarka CAR-NK waxay leedahay heer wax ku ool ah oo ah 73%, waxaana lagu qorayaa tijaabooyinka kiliinikada gudaha. Kansarka difaaca jirka waa kala qaybsanaan.